Please assess the completion status of the following clinical trial:

Trial Title: Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient completed Study 17972A.~* The patient and the patient's caregiver or identified responsible person is able to read and understand the Informed Consent Form.~* The patient has signed the Informed Consent Form specific for Study 17972B.~* The patient can potentially benefit from 24 weeks of treatment with Lu AF11167 according to the investigator's clinical judgment.~Exclusion Criteria:~* The patient has any current primary psychiatric disorder other than schizophrenia diagnosed during study 17972A~* The patient, in the opinion of the investigator, is at significant risk of suicide~Other in- and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lu AF11167 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).